Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00976170 · ClinicalTrials.gov registry record · Phase 1
Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)
A Phase 1 study, sponsored by Chugai Pharmaceutical.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT00976170 is a Phase 1 study that has completed, run by Chugai Pharmaceutical. The registered enrollment target is 42 participants.
The verdict
NCT00976170, a Phase 1 study, has completed, sponsored by Chugai Pharmaceutical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This phase I trial is studying the safety and best dose of GC33 and Sorafenib in combination in patients with advanced or metastatic liver cancer.
Interventions
- DRUG Sorafenib
- DRUG GC33(RO5137382)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2009-09 |
| Est. Completion | 2014-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00976170
The ClinicalTrials.gov registry entry for NCT00976170 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chugai Pharmaceutical, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sorafenib is the first listed.
NCT00976170 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00976170 about?
NCT00976170 is a clinical study titled "Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)". This phase I trial is studying the safety and best dose of GC33 and Sorafenib in combination in patients with advanced or metastatic liver cancer.
What is the current status of trial NCT00976170?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2009-09. Estimated completion is 2014-09.
What interventions are being tested in trial NCT00976170?
The interventions under investigation include: Sorafenib (DRUG), GC33(RO5137382) (DRUG).
Who is sponsoring clinical trial NCT00976170?
This trial is sponsored by Chugai Pharmaceutical, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.